| Date |
Subject |
Media |
| 2025-08-11 |
APN LifeSciences Secures Strategic Investment from ADDF
|
Taiwan's biotech innovation gains global recognition. APN LifeSciences has announced a strategic investment from the Alzheimer’s Drug Discovery Foundation (ADDF). Founded by the family behind global beauty giant Estée Lauder, the ADDF’s backing will accelerate the development of APN 1607. |
| 2025-08-11 |
Migraine Diagnosis with a Single Drop of Blood Becomes Reality: Taiwan Team Led by Taipei Veterans General Hospital Develops Predictive Model with 90% Accuracy Over Five Years
|
Migraine is one of the most common neurological disorders globally, affecting an estimated 15% of the population, with over 1 billion sufferers worldwide—three times more common in women than in men. According to the Global Burden of Disease Study, migraine is the second leading cause of disability among individuals aged 15 to 49, severely impacting work, education, and quality of life. In Taiwan, approximately 2 million people experience migraine attacks each year. |
| 2025-08-11 |
GlycoNex Advances Targeted Gastric Cancer Antibody Drug GNX1021, Aiming to Launch Phase I Clinical Trial in Q2 2026
|
GlycoNex, a Taiwan-based biopharmaceutical company, announced that its antibody-drug conjugate (ADC) GNX1021, developed in collaboration with OP NanoPharma, has successfully completed pre-fill testing for clinical trial use. The results confirmed process stability and product quality in accordance with international standards. In July, GLP toxicology studies in rats and cynomolgus monkeys were also initiated, with completion expected by the fourth quarter of this year. The company plans to submit clinical trial applications to the health authorities in Taiwan and Japan in the first quarter of 2026, with the goal of launching a Phase I clinical trial in the second quarter of 2026. |
| 2025-08-11 |
Libo Pharma Completes NT$850 Million Fundraising to Accelerate Global Development of Immunotherapy Drug NM-IL-12, Targeting Q4 Emerging Stock Board Listing
|
On July 21, Libo Pharma announced the successful completion of a NT$850 million fundraising round. In addition to continued support from its parent company LIH PAO GROUP, original venture capital shareholders Beiley Biofund, Zhongjia Investment, and President International Development, this round also attracted several new investors, including Taishin Venture Capital, CDIB Healthcare II Venture Fund, Capital Venture Management, CTBC Venture Capital, and Qisda Group. Despite global economic uncertainties and tariff concerns, the company achieved this fundraising against the odds, underscoring the market’s strong confidence in Libo Pharma’s R&D capabilities and future potential. |
| 2025-08-11 |
Oneness Biotech’s New Drug “Fespixon” Receives Marketing Approval from Indonesia’s National Agency of Drug and Food Control
|
On July 18, Oneness Biotech announced that its new drug Fespixon, developed for the treatment of diabetic foot ulcers, has been granted marketing authorization by Indonesia’s National Agency of Drug and Food Control (BPOM).
The company stated that it received notification from its Indonesian consulting firm that the drug registration for Fespixon had been approved by BPOM. Following the commercial launch of this new drug in Indonesia, Oneness Biotech will pay a sales royalty to the licensor in accordance with the terms of their licensing agreement. |
| 2025-08-11 |
EirGenix Debuts on TWSE Today, Forms ADC Alliance with TTY Biopharm
|
EirGenix (Taiwan Biotech Co., Ltd.) is officially transitioning to the Taiwan Stock Exchange (TWSE) today (21st). Chairman Dr. Lee-Cheng Liu announced that in addition to the continued momentum of its CDMO business, the company has entered a strategic alliance with TTY Biopharm for the development of ADCs (antibody-drug conjugates) that combine large-molecule biologics with small-molecule drugs. Furthermore, the company’s first biosimilar for breast cancer, EG12014, has already obtained two drug licenses, which are expected to further boost its growth trajectory. |
| 2025-08-11 |
PharmaEssentia's New Drug Ropeg Applies for Regulatory Approval in Canada, Expanding Its Global PV Market Footprint
|
Last Friday (the 18th), PharmaEssentia announced a major development: the company has submitted a New Drug Submission (NDS) in Canada for its proprietary therapy BESREMi (Ropeginterferon alfa-2b, referred to as Ropeg or P1101) for the treatment of polycythemia vera (PV), marking its official entry into the Canadian market. |
| 2025-08-11 |
Enimmune Submits Marketing Authorization Application for EV71 Vaccine in Vietnam
|
Emerging biotech stock Enimmune announced on the 20th that its independently developed enterovirus 71 (EV71) vaccine, EnVAX-A71, has been officially submitted for marketing authorization in Vietnam. The submission was made on July 18 by its local partner, the Vietnamese state-owned company VABIOTECH, to the Drug Administration of Vietnam (DAV) under the Ministry of Health. |
| 2025-08-07 |
Collaborative Breakthrough by NCKU Cancer-Cardiology Team: New Drug Proven Effective in Preventing Cardiotoxicity from Cancer Treatments
|
The Cardiology Department, Division of Medical Oncology, and Breast Surgery Department at National Cheng Kung University Hospital (NCKU Hospital) have successfully completed the world’s first Phase II clinical trial using a next-generation heart failure drug—Angiotensin Receptor-Neprilysin Inhibitor (ARNI)—to prevent cancer therapy-related cardiac dysfunction (CTRCD). This collaborative research marks a major step forward in achieving safer and more effective integrative care for cancer patients. |
| 2025-08-07 |
Locus Cell's Order Book Extends Through End of 2025
|
Locus Cell’s large-scale CDMO facility for cell therapy in Zhubei is nearing completion and gearing up for production. The company announced yesterday (17th) that the construction of the Zhubei plant, built with an investment exceeding NT$900 million, will be completed in August this year. An additional NT$547 million will be invested in interior construction, with the goal of officially beginning production in the first quarter of next year. |
